These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 10468676

  • 1. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
    Van Rensburg CJ, Honiball PJ, Van Zyl JH, Grundling HD, Eloff FP, Spies SK, Simjee AE, Theron I, Fischer R, Louw JA.
    Aliment Pharmacol Ther; 1999 Aug; 13(8):1023-8. PubMed ID: 10468676
    [Abstract] [Full Text] [Related]

  • 2. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
    Mössner J, Koop H, Porst H, Wübbolding H, Schneider A, Maier C.
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1087-92. PubMed ID: 9663834
    [Abstract] [Full Text] [Related]

  • 3. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis.
    Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C.
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1481-91. PubMed ID: 10571605
    [Abstract] [Full Text] [Related]

  • 4. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
    Adamek RJ, Behrendt J, Wenzel C.
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
    [Abstract] [Full Text] [Related]

  • 5. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
    Corinaldesi R, Valentini M, Belaïche J, Colin R, Geldof H, Maier C.
    Aliment Pharmacol Ther; 1995 Dec; 9(6):667-71. PubMed ID: 8824655
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis.
    van Rensburg CJ, Honiball PJ, Grundling HD, van Zyl JH, Spies SK, Eloff FP, Simjee AE, Segal I, Botha JF, Cariem AK, Marks IN, Theron I, Bethke TD.
    Aliment Pharmacol Ther; 1996 Jun; 10(3):397-401. PubMed ID: 8791969
    [Abstract] [Full Text] [Related]

  • 7. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Adler J, Eklund S.
    Aliment Pharmacol Ther; 2005 Nov 01; 22(9):803-11. PubMed ID: 16225489
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
    Kovacs TO, Wilcox CM, DeVault K, Miska D, Bochenek W, Pantoprozole US Gerd Study Group B.
    Aliment Pharmacol Ther; 2002 Dec 01; 16(12):2043-52. PubMed ID: 12452936
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children.
    Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P.
    J Pediatr Gastroenterol Nutr; 2003 Feb 01; 36(2):261-5. PubMed ID: 12548064
    [Abstract] [Full Text] [Related]

  • 10. [Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group].
    Gallo S, Dibildox M, Moguel A, Di Silvio M, Rodríguez F, Almaguer I, García C.
    Rev Gastroenterol Mex; 1998 Feb 01; 63(1):11-6. PubMed ID: 10068743
    [Abstract] [Full Text] [Related]

  • 11. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
    Plein K, Hotz J, Wurzer H, Fumagalli I, Lühmann R, Schneider A.
    Eur J Gastroenterol Hepatol; 2000 Apr 01; 12(4):425-32. PubMed ID: 10783996
    [Abstract] [Full Text] [Related]

  • 12. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.
    Pilotto A, Leandro G, Franceschi M, Ageing and Acid-Related Disease Study Group.
    Aliment Pharmacol Ther; 2003 Jun 01; 17(11):1399-406. PubMed ID: 12786634
    [Abstract] [Full Text] [Related]

  • 13. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
    Holtmann G, Cain C, Malfertheiner P.
    Gastroenterology; 1999 Jul 01; 117(1):11-6. PubMed ID: 10381904
    [Abstract] [Full Text] [Related]

  • 14. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial.
    Mössner J, Hölscher AH, Herz R, Schneider A.
    Aliment Pharmacol Ther; 1995 Jun 01; 9(3):321-6. PubMed ID: 7654895
    [Abstract] [Full Text] [Related]

  • 15. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.
    Bardhan KD, Van Rensburg C.
    Aliment Pharmacol Ther; 2001 Oct 01; 15(10):1585-91. PubMed ID: 11563998
    [Abstract] [Full Text] [Related]

  • 16. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, Gatz G.
    Digestion; 2003 Oct 01; 67(1-2):6-13. PubMed ID: 12743434
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
    van Zyl JH, de K Grundling H, van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, Fischer R, Bethke T.
    Eur J Gastroenterol Hepatol; 2000 Feb 01; 12(2):197-202. PubMed ID: 10741935
    [Abstract] [Full Text] [Related]

  • 18. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D, Paré P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group.
    Am J Gastroenterol; 2001 Oct 01; 96(10):2849-57. PubMed ID: 11695354
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS, Berardi RR.
    J Am Pharm Assoc (Wash); 2000 Oct 01; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
    Stupnicki T, Dietrich K, González-Carro P, Straszak A, Terjung A, Thomas KB, Lühmann R, Fischer R.
    Digestion; 2003 Oct 01; 68(4):198-208. PubMed ID: 14707396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.